Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.63
- Piotroski Score 4.00
- Grade Buy
- Symbol (ARQT)
- Company Arcutis Biotherapeutics, Inc.
- Price $10.04
- Changes Percentage (-1.33%)
- Change -$0.14
- Day Low $9.84
- Day High $10.42
- Year High $13.17
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $27.50
- High Stock Price Target $51.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.79
- Trailing P/E Ratio -2.59
- Forward P/E Ratio -2.59
- P/E Growth -2.59
- Net Income $-262,140,000
Income Statement
Quarterly
Annual
Latest News of ARQT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc is a biopharmaceutical company focusing on dermatological treatments. Insider selling trends, with 21 sales and 2 buys in the past year, reflect a valuation of $1.27 billio...
By Yahoo! Finance | 4 weeks ago -
Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is a promising small-cap healthcare stock focused on dermatological treatments. Its lead product, ZORYVE, shows market potential, with hedge fund interest and...
By Yahoo! Finance | 1 month ago -
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long
Arcutis Biotherapeutics is close to breaking even, with analysts predicting profitability in 2026. However, its high debt level raises investment risk. The company's growth prospects and path to profi...
By Yahoo! Finance | 1 month ago
